Generation and characterization of mirikizumab, a humanized monoclonal antibody targeting the p19 subunit of IL-23 [Drug Discovery and Translational Medicine]
ASPET
SEPTEMBER 15, 2023
Mirikizumab effectively inhibits the interaction of IL-23 with its receptor, and potently blocks IL-23-induced IL-17 production in cell-based assays while preserving the function of IL-12. In both local and systemic in vivo mouse models, mirikizumab blocked IL-23-induced keratin mRNA or IL-17 production, respectively.
Let's personalize your content